Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Pediatr Pulmonol ; 57(1): 49-56, 2022 01.
Article in English | MEDLINE | ID: covidwho-1437078


OBJECTIVE: Few studies have explored the clinical features in children infected with SARS-CoV-2 and other common respiratory viruses, including respiratory syncytial virus (RSV), Influenza virus (IV), and adenovirus (ADV). Herein, we reported the clinical characteristics and cytokine profiling in children with COVID-19 or other acute respiratory tract infections (ARTI). METHODS: We enrolled 20 hospitalized children confirmed as COVID-19 positive, 58 patients with ARTI, and 20 age and sex-matched healthy children. The clinical information and blood test results were collected. A total of 27 cytokines and chemokines were measured and analyzed. RESULTS: The median age in the COVID-19 positive group was 14.5 years, which was higher than that of the ARTI groups. Around one-third of patients in the COVID-19 group experienced moderate fever, with a peak temperature of 38.27°C. None of the patients displayed wheezing or dyspnea. In addition, patients in the COVID-19 group had lower white blood cells, platelet counts as well as a neutrophil-lymphocyte ratio. Lower serum concentrations of 14 out of 27 cytokines were observed in the COVID-19 group than in healthy individuals. Seven cytokines (IL-1Ra, IL-1ß, IL-9, IL-10, TNF-α, MIP-1α, and VEGF) changed serum concentration in COVID-19 compared with other ARTI groups. CONCLUSION: Patients with COVID-19 were older and showed milder symptoms and a favorable prognosis than ARTI caused by RSV, IV, and ADV. There was a low grade or constrained innate immune reaction in children with mild COVID-19.

COVID-19 , Respiratory Syncytial Virus Infections , Respiratory Syncytial Virus, Human , Respiratory Tract Infections , Adolescent , China/epidemiology , Humans , Infant , Respiratory Syncytial Virus Infections/diagnosis , Respiratory Tract Infections/diagnosis , SARS-CoV-2
SciFinder; 2020.
Preprint | SciFinder | ID: ppcovidwho-5255


A review. Since Dec. 2019, Wuhan City, Hubei Province has discovered many cases of new coronavirus-infected pneumonia patients. With the spread of the epidemic, such cases have also been found in other regions of China and abroad. As an acute respiratory infectious disease, the disease was included in Category B infectious diseases as stipulated in the Law of the People's Republic of China on the Prevention and Control of Infectious Diseases on Jan. 20, 2020, and is managed as Category A infectious diseases. WHO in 2020 On Jan. 30, it was announced that the new coronavirus epidemic was listed as a public health emergency of international concern. With the progress of the epidemic and the development of etiol. testing, reports of children 's infections are gradually increasing. There are many cases of children 's reports, and there are cases of infant and newborn infections. With the deepening of disease knowledge and the accumulation of experience in diagnosis and treatment, the National Health and Health Commission has now formulated the "New Coronavirus Infection Pneumonia Diagnosis and Treatment Program (Trial Sixth Edition)" [1]. The Pediatric Branch of the Chinese Medical Association is concluding On the basis of confirmed cases of children, the "Diagnosis and Prevention Recommendations for Children's 2019 New Coronavirus Infection (Trial First Version)" [2], recently issued by the International Virus Classification Committee(International Committee on Taxonomy of Viruses, ICTV) officially identified the name of the new coronavirus as severe acute Respiratory syndrome coronavirus type 2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2). According to the epidemic situation in Chongqing, combined with the characteristics of children's diseases, on the basis of the revision of the "Diagnosis and Treatment Plan for New Coronavirus Infection in Children's Hospital of Chongqing Medical University (First Edition)", the "New Coronavirus for Children in Children's Hospital of Chongqing Medical University" was formulated Infection diagnosis and treatment plan (trial second edition) ".

Genes Dis ; 7(4): 535-541, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-52595


In December 2019, the corona virus disease 2019 (COVID-19) caused by novel coronavirus (SARS-CoV-2) emerged in Wuhan, China and rapidly spread worldwide. Few information on clinical features and immunological profile of COVID-19 in paediatrics. The clinical features and treatment outcomes of twelve paediatric patients confirmed as COVID-19 were analyzed. The immunological features of children patients was investigated and compared with twenty adult patients. The median age was 14.5-years (range from 0.64 to 17), and six of the patients were male. The average incubation period was 8 days. Clinically, cough (9/12, 75%) and fever (7/12, 58.3%) were the most common symptoms. Four patients (33.3%) had diarrhea during the disease. As to the immune profile, children had higher amount of total T cell, CD8+ T cell and B cell but lower CRP levels than adults (P < 0.05). Ground-glass opacity (GGO) and local patchy shadowing were the typical radiological findings on chest CT scan. All patients received antiviral and symptomatic treatment and the symptom relieved in 3-4 days after admitted to hospital. The paediatric patients showed mild symptom but with longer incubation period. Children infected with SARS-CoV-2 had different immune profile with higher T cell amount and low inflammatory factors level, which might ascribed to the mild clinical symptom. We advise that nucleic acid test or examination of serum IgM/IgG antibodies against SARS-CoV-2 should be taken for children with exposure history regardless of clinical symptom.